Bentyl
Dicyclomine Hydrochloride
Sourced from the FDA Orange Book
Key dates
Key dates
Approval
FDA approval date of this drug product.
Oct 15, 1984
42 yr 4 mo ago
Today
Pharmaceutical detail
Pharmaceutical detail
Active ingredient
DICYCLOMINE HYDROCHLORIDE
Strength
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 007409
Product number
003
Marketing status
Discontinued
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Other strengths in NDA 007409
Active-ingredient family
This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 1984BentylBrand (NDA)
NDA 008370 · Abbvie
- 1984BentylBrand (NDA)
NDA 007961 · Aptalis Pharma US
- 2025Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 219242 · Rising
- 2025Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 218310 · Prinston Inc
- 2024Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 218952 · Rising
- 2024Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 214332 · Somerset Theraps LLC
- 2024Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 214333 · Somerset Theraps LLC
- 2024Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 218018 · Annora Pharma
- 2024Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 217566 · Annora Pharma
- 2023Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 217531 · Prinston Inc
- 2023Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 217916 · Bionpharma
- 2023Dicyclomine HydrochlorideGeneric (ANDA)
ANDA 216782 · Twi Pharms
Listed patents
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Bentyl — frequently asked questions
Approval, therapeutic equivalence, patents, and exclusivity for this product, from the FDA Orange Book.
Built directly from the FDA Orange Book data file. This product page links back to the Dicyclomine Hydrochloride active-ingredient family, which is the canonical reference for generics, patents, and exclusivity across all strengths.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.

